Greg Ogilvie, founder of the Angel Care Cancer Center at California Veterinary Specialists, has spent his life searching for new and improved cancer treatments for animals and their families. An award-winning, diverse and highly esteemed oncologist and veterinary researcher, Dr. Ogilvie works with a dedicated and highly qualified team of oncologists, oncology nurses and technicians testing the safety and efficacy of groundbreaking cancer treatments on dogs.
Dr. Ogilvie is directing a ground breaking canine clinical trial using a new and revolutionary non-invasive medical device called Voyager. "Voyager is just beginning its voyage as we are beginning the process of identifying the cancers its most effective to treat. It seems to have a broad spectrum of efficacy while being quite safe."
The Voyager results are remarkable. Rapid and durable tumor response has been seen in many patients, resulting in partial and complete remissions. After one week of treatment, Voyager safely eliminated 90% of one patient's malignant mass tumor.
The world class veterinary oncology teams at CVS Angel Care are inviting families to enroll their beloved canine cancer patients in this clinical trials with the firm believe that Voyager therapy can help, without hurting, and that the results of this clinical trial can greatly benefit canine cancer patients and eventually people who have similar cancers. "Our whole passion here at CVS Angel Care is being able to identify that which can bring help, compassion and hope to animals with cancer not just for our own hospital but for the world as a whole."
"When given an opportunity to actually have something that can help their pet, it's very empowering for them to know that they're going to have the opportunity to help their animal with cancer. Being a part of something bigger, being a part of an amazing discovery that will help literally thousands of animals and potentially people with cancer is something that they become very excited about."
Your dog may be eligible to enter this study if he or she has a measurable tumor, is in good health otherwise, and if you are willing to visit one of our three Angel Care Cancer Centers for weekly evaluations and assessments. Our centers are located in Murrieta, Carlsbad and Ontario California. For more information on how your dog can enter the Voyager Cancer Treatment Trial:
Call: (760) 431-2273
In case you missed it, check out last week’s KUSI-TV live segment with Dr. Ogilvie as he discusses cancer treatment for animals.
We are in a process developing a new therapy for dogs with lymphoma that harnesses the immune system to destroy its own cancer. With appropriate therapy we are able to not only enhance and improve their quality of life but also extend that life and reduce the need for chemotherapy. This non-invasive, fully-funded study is one in which we take animals that have lymphoma and willing families who are excited about exploring new opportunities that will enhance and improve the quality of life of a pet with cancer. The veterinary health team...
In honor on National Veterinary Technician Week, CVS would like to thank each and every one of our dedicated technicians for their hard work, compassionate care and invaluable service to the veterinary field. Pictured are a few of our wonderful technicians from all three hospitals.
The investigative FOXNews journalists caught up with the clinicians, nurses and researchers at California Veterinary Specialists Angel Care Cancer Center to learn how an invisible virus is being evaluated as the next generation of compassionate cancer cures in dogs, cats and people. Angel Care Cancer Center, a separate but allied non-profit research organization, the Special Care Foundation for Companion Animals and the San Diego based company Genelux have teamed up to affirm the safety an efficacy of a new cancer killing virus. The therapy
Inclusion Criteria: Clinically healthy dogs with palpable, measurable cyto- or histologically confirmed malignancy and acceptable recent chest radiographs and blood work. Study will cover costs of each drug signal therapy delivered by a device that is placed over the palpable 1-6 cm tumor and all in-hospital rechecks and restaging at CVS.